FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897945733> ?p ?o ?g. }

• W2897945733 endingPage "1104" @default.
• W2897945733 startingPage "1093" @default.
• W2897945733 abstract "Though anti-tumor necrosis factor agents (anti-TNFs) have been recommended as third-line therapy for sarcoidosis, an up-to-date systematic synthesis of their efficacy and safety is lacking.To systematically review the literature to characterize the efficacy and safety of anti-TNFs in sarcoidosis.All countries and treatment settings were included.We searched MEDLINE, EMBASE, CINAHL, Web of Science, ClinicalTrials.gov, Cochrane Library, and Google Scholar from inception to November 27, 2017. Studies of five or more cases of sarcoidosis treated with anti-TNFs were included. Descriptive statistics were performed.Sixty-five studies (including five randomized controlled trials [RCTs]) were identified, comprising 1525 patients. For pulmonary sarcoidosis, one RCT found infliximab (IFX) significantly improved vital capacity vs. placebo; a second detected no difference. In non-randomized studies, IFX improved pulmonary function in 79% of patients. For cutaneous sarcoidosis, compared to placebo, adalimumab (ADA) showed greater Physician Global Assessment response and significantly reduced target lesion area, and IFX significantly decreased Sarcoidosis Area and Severity Index induration and erythema scores. In non-randomized studies of cutaneous, ocular, neurologic, and multisystem sarcoidosis, IFX improved 89%, 69%, 77%, and 71% of cases, respectively. ADA improved 77% of ocular sarcoidosis cases. IFX displayed a steroid-sparing effect. Half of patients relapsed after discontinuation of IFX, ADA, etanercept, or certolizumab pegol. In RCTs, compared to placebo, anti-TNFs had comparable overall and serious adverse events and slightly more serious infections.Available evidence suggests the efficacy and safety of IFX in pulmonary, cutaneous, ocular, neurologic, and multisystem sarcoidosis, and ADA in cutaneous and ocular sarcoidosis." @default.
• W2897945733 created "2018-10-26" @default.
• W2897945733 creator A5025341978 @default.
• W2897945733 creator A5026274771 @default.
• W2897945733 creator A5033903141 @default.
• W2897945733 creator A5057134704 @default.
• W2897945733 creator A5071668456 @default.
• W2897945733 date "2019-06-01" @default.
• W2897945733 modified "2023-10-16" @default.
• W2897945733 title "Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety" @default.
• W2897945733 cites W1128414353 @default.
• W2897945733 cites W1138553268 @default.
• W2897945733 cites W1487724554 @default.
• W2897945733 cites W1830489878 @default.
• W2897945733 cites W1965126419 @default.
• W2897945733 cites W1979164636 @default.
• W2897945733 cites W1980384413 @default.
• W2897945733 cites W1987208829 @default.
• W2897945733 cites W1994138560 @default.
• W2897945733 cites W1995030115 @default.
• W2897945733 cites W2000894943 @default.
• W2897945733 cites W2000902902 @default.
• W2897945733 cites W2002906466 @default.
• W2897945733 cites W2005501262 @default.
• W2897945733 cites W2020060831 @default.
• W2897945733 cites W2025024872 @default.
• W2897945733 cites W2028051076 @default.
• W2897945733 cites W2028719806 @default.
• W2897945733 cites W2038595075 @default.
• W2897945733 cites W2040958678 @default.
• W2897945733 cites W2045831110 @default.
• W2897945733 cites W2046520473 @default.
• W2897945733 cites W2059731037 @default.
• W2897945733 cites W2065893580 @default.
• W2897945733 cites W2076158450 @default.
• W2897945733 cites W2080002549 @default.
• W2897945733 cites W2088228080 @default.
• W2897945733 cites W2090142741 @default.
• W2897945733 cites W2094921964 @default.
• W2897945733 cites W2100052996 @default.
• W2897945733 cites W2112441575 @default.
• W2897945733 cites W2114911311 @default.
• W2897945733 cites W2117666935 @default.
• W2897945733 cites W2120099882 @default.
• W2897945733 cites W2122283654 @default.
• W2897945733 cites W2122408285 @default.
• W2897945733 cites W2130860647 @default.
• W2897945733 cites W2131718547 @default.
• W2897945733 cites W2138783361 @default.
• W2897945733 cites W2142665211 @default.
• W2897945733 cites W2142835745 @default.
• W2897945733 cites W2154811627 @default.
• W2897945733 cites W2154870890 @default.
• W2897945733 cites W2166970720 @default.
• W2897945733 cites W2169804326 @default.
• W2897945733 cites W2171270498 @default.
• W2897945733 cites W2277108300 @default.
• W2897945733 cites W2314288672 @default.
• W2897945733 cites W2341426192 @default.
• W2897945733 cites W2472937099 @default.
• W2897945733 cites W2499246258 @default.
• W2897945733 cites W2555794806 @default.
• W2897945733 cites W2591931659 @default.
• W2897945733 cites W2594015687 @default.
• W2897945733 cites W2594398375 @default.
• W2897945733 cites W2620055410 @default.
• W2897945733 cites W2741130337 @default.
• W2897945733 cites W2763324892 @default.
• W2897945733 cites W2764110357 @default.
• W2897945733 cites W2792912603 @default.
• W2897945733 cites W3044254922 @default.
• W2897945733 cites W336748417 @default.
• W2897945733 cites W4210995779 @default.
• W2897945733 cites W4244164401 @default.
• W2897945733 doi "https://doi.org/10.1016/j.semarthrit.2018.10.005" @default.
• W2897945733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30446173" @default.
• W2897945733 hasPublicationYear "2019" @default.
• W2897945733 type Work @default.
• W2897945733 sameAs 2897945733 @default.
• W2897945733 citedByCount "49" @default.
• W2897945733 countsByYear W28979457332019 @default.
• W2897945733 countsByYear W28979457332020 @default.
• W2897945733 countsByYear W28979457332021 @default.
• W2897945733 countsByYear W28979457332022 @default.
• W2897945733 countsByYear W28979457332023 @default.
• W2897945733 crossrefType "journal-article" @default.
• W2897945733 hasAuthorship W2897945733A5025341978 @default.
• W2897945733 hasAuthorship W2897945733A5026274771 @default.
• W2897945733 hasAuthorship W2897945733A5033903141 @default.
• W2897945733 hasAuthorship W2897945733A5057134704 @default.
• W2897945733 hasAuthorship W2897945733A5071668456 @default.
• W2897945733 hasConcept C126322002 @default.
• W2897945733 hasConcept C141071460 @default.
• W2897945733 hasConcept C142724271 @default.
• W2897945733 hasConcept C16005928 @default.
• W2897945733 hasConcept C168563851 @default.
• W2897945733 hasConcept C17991360 @default.
• W2897945733 hasConcept C197934379 @default.

• next